BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1318 related articles for article (PubMed ID: 31429903)

  • 1. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
    Nelson HD; Huffman LH; Fu R; Harris EL;
    Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
    JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
    U.S. Preventive Services Task Force
    Ann Intern Med; 2005 Sep; 143(5):355-61. PubMed ID: 16144894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should I Be Tested for BRCA Mutations?
    Jin J
    JAMA; 2019 Aug; 322(7):702. PubMed ID: 31429898
    [No Abstract]   [Full Text] [Related]  

  • 10. USPSTF recommends BRCA testing in women based on familial history.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E6. PubMed ID: 25618620
    [No Abstract]   [Full Text] [Related]  

  • 11. BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care.
    Parente DJ
    J Am Board Fam Med; 2020; 33(6):885-893. PubMed ID: 33219067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing for hereditary breast and ovarian cancer in the southeastern United States.
    Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
    Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
    [No Abstract]   [Full Text] [Related]  

  • 17. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
    JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.
    Søgaard M; Kjaer SK; Gayther S
    Acta Obstet Gynecol Scand; 2006; 85(1):93-105. PubMed ID: 16521688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations.
    Ann Intern Med; 2005 Sep; 143(5):I47. PubMed ID: 16144889
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 66.